At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EIKN Eikon Therapeutics
Pre-Mkt 10-28 05:56:12 EDT
5.55
+0.01
+0.09%
盘前5.46
-0.08-1.53%
05:52 EDT
High5.99Low5.51Vol697.27K
Open5.56D1 Closing5.54Amplitude8.66%
Mkt Cap299.34MTradable Cap97.86MTotal Shares53.98M
T/O3.94MT/O Rate3.95%Tradable Shares17.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Brian Cheng Initiates Buy on Eikon Therapeutics, Citing Advancing Oncology Pipeline and Strategic PARP1/WRN Programs
TIPRANKS  ·  10-27 11:45
Brian Cheng Initiates Buy on Eikon Therapeutics, Citing Advancing Oncology Pipeline and Strategic PARP1/WRN Programs
Eikon Therapeutics presents updated EIK1001 data at ESMO
TIPRANKS  ·  10-26 18:05
Eikon Therapeutics presents updated EIK1001 data at ESMO
Eikon Therapeutics' Eik1001 Combination Shows 72.4% Response Rate in Squamous Lung Cancer Trial
Reuters  ·  10-26 18:01
Eikon Therapeutics' Eik1001 Combination Shows 72.4% Response Rate in Squamous Lung Cancer Trial
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
GlobeNewswire  ·  10-26 18:00
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Eikon Therapeutics Highlights Promising PARP1 and WRN Data
TIPRANKS  ·  10-23
Eikon Therapeutics Highlights Promising PARP1 and WRN Data
Eikon Therapeutics Reports 26.4% Response Rate for Eik1003-Paclitaxel Combination in Phase 1/2 Trial
Reuters  ·  10-23
Eikon Therapeutics Reports 26.4% Response Rate for Eik1003-Paclitaxel Combination in Phase 1/2 Trial
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
GlobeNewswire  ·  10-23
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Eikon Therapeutics to present abstracts on clinical candidates at ESMO 2026
TIPRANKS  ·  10-19
Eikon Therapeutics to present abstracts on clinical candidates at ESMO 2026
Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMO
Reuters  ·  10-19
Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMO
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
GlobeNewswire  ·  10-19
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Eikon Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones  ·  10-17
Eikon Therapeutics Initiated at Buy by HC Wainwright & Co.
HC Wainwright Initiates Coverage on Eikon Therapeutics With Buy Rating, $23 Price Target
MT Newswires Live  ·  10-16
HC Wainwright Initiates Coverage on Eikon Therapeutics With Buy Rating, $23 Price Target
Eikon Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $23
THOMSON REUTERS  ·  10-16
Eikon Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $23
Eikon Therapeutics Files IND for Prostate Cancer Drug EIK1006
MT Newswires Live  ·  10-15
Eikon Therapeutics Files IND for Prostate Cancer Drug EIK1006
Eikon Therapeutics submits EIK1006 IND application to FDA
TIPRANKS  ·  10-15
Eikon Therapeutics submits EIK1006 IND application to FDA
Eikon Therapeutics Submits Ind for Novel Androgen Receptor Antagonist Eik1006 in Prostate Cancer
THOMSON REUTERS  ·  10-15
Eikon Therapeutics Submits Ind for Novel Androgen Receptor Antagonist Eik1006 in Prostate Cancer
Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth?
Simply Wall St.  ·  10-14
Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth?
Major Investor Makes Bold Move on Eikon Therapeutics Shares
TIPRANKS  ·  09-09
Major Investor Makes Bold Move on Eikon Therapeutics Shares
Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million
Reuters  ·  09-09
Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million
Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer
Reuters  ·  09-03
Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Introduction

Company Name.
Eikon Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eikon Therapeutics, Inc. was incorporated in Delaware on July 9, 2019. It is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, primarily in oncology. The leadership team has a notable track record of successfully developing impactful drugs. The company's strategy leverages a proprietary technology platform to create novel therapies, with lead candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.
Issue price:
--